202 related articles for article (PubMed ID: 25351365)
1. Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Zhang S; Xie C; Wang Q; Liu Z
Sci Rep; 2014 Oct; 4():6811. PubMed ID: 25351365
[TBL] [Abstract][Full Text] [Related]
2. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
[TBL] [Abstract][Full Text] [Related]
3. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
[TBL] [Abstract][Full Text] [Related]
4. Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Wang XS; Zhang ZR; Zhang XR; Chen SY; Shao B; Xie CL
Biomed Pharmacother; 2018 Nov; 107():769-776. PubMed ID: 30142538
[TBL] [Abstract][Full Text] [Related]
5. Dopamine binds calmodulin during autoregulation of dopaminergic D2 receptor signaling through CaMKIIα-calmodulin complex.
Laoye BJ; Okurumeh OA; Obagaye OV; Olagunju MO; Bankole OO; Olubiyi OO; Ogundele OM
J Recept Signal Transduct Res; 2016; 36(3):271-7. PubMed ID: 26446938
[TBL] [Abstract][Full Text] [Related]
6. The Dynamics of Dopamine D
Liu K; Song M; Gao S; Yao L; Zhang L; Feng J; Wang L; Gao R; Wang Y
Neurosci Bull; 2023 Sep; 39(9):1411-1425. PubMed ID: 37022638
[TBL] [Abstract][Full Text] [Related]
7. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
Gan J; Qi C; Liu Z
Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
10. Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
Brown AM; Deutch AY; Colbran RJ
Eur J Neurosci; 2005 Jul; 22(1):247-56. PubMed ID: 16029214
[TBL] [Abstract][Full Text] [Related]
11. In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Mela F; Marti M; Bido S; Cenci MA; Morari M
Neurobiol Dis; 2012 Jan; 45(1):573-82. PubMed ID: 22001605
[TBL] [Abstract][Full Text] [Related]
12. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
13. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
14. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
15. NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
Wu N; Song L; Yang X; Yuan W; Liu Z
Clin Interv Aging; 2013; 8():347-52. PubMed ID: 23569367
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of striatal dopamine D
Wang Y; Yao L; Gao S; Zhang G; Zhang Q; Liu W; Zhou Y; Sun Y; Feng J; Liu J
Brain Res; 2021 Mar; 1754():147266. PubMed ID: 33422541
[TBL] [Abstract][Full Text] [Related]
17. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
[TBL] [Abstract][Full Text] [Related]
18. Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Ba M; Kong M; Ma G
Drug Des Devel Ther; 2015; 9():199-206. PubMed ID: 25565773
[TBL] [Abstract][Full Text] [Related]
19. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
20. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z
Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
